Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility, for example celecoxib, in an immediate-release fraction and a controlled-release, slow-release, programmed-release, timed-release, pulse-release, sustained-release or extended-release fraction. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.
Type:
Grant
Filed:
December 20, 2000
Date of Patent:
May 22, 2007
Assignee:
Pharmacia Corporation (of Pfizer, Inc.)
Inventors:
Subhash Desai, Sreekant R. Nadkarni, Randy J. Wald, Gary A. DeBrincat
Abstract: A novel fenofibrate-containing composition having equivalent bioavailability, when compared to conventional capsules, is effective in reducing the size of the conventional capsule preparations. The fenofibrate-containing composition comprises the following formula: (a) fenofibrate 100 parts by weight, (b) a solid surfactant 3 to 4 parts by weight, (c) lactose 1 to 2 parts by weight, and (d) magnesium stearate 1 to 2 parts by weight, in admixture with a binder and a disintegrator, wherein the sum of said binder and said disintegrator is 17 to 20 parts by weight, and the fenofibrate and the solid surfactant are co-micronizates.
Abstract: Nanometer particles of poorly water-soluble or substantially water-insoluble compound are produced by finely-spraying a non-aqueous solution of said compound into a heated and fluidized bed of carrier excipient. The resulting product consists of a free flowing mixture of relatively large particles of carrier excipient and nanometer sized particles (less than 3 ?m)) of compound.
Abstract: Irritation upon injection of a formulation containing propofol is reduced or substantially eliminated by administering a stable, sterile, and antimicrobial aqueous dispersion comprising a water-insoluble microdroplet matrix of mean diameter from about 50 nm to about 1000 nm consisting essentially of about 1% to about 15% of propofol, up to about 7% of a propofol-soluble diluent, and about 0.8% to about 4% of a surface stabilizing amphiphilic aent. The aqueous phase includes a pharmaceutically acceptable water-soluble polyhydroxy tonicity modifier. The propofol-containing dispersion is devoid of additional bactericidal or bacteriostatic preservative agents.
Type:
Grant
Filed:
March 26, 2001
Date of Patent:
May 9, 2006
Assignee:
Jagotec AG
Inventors:
Awadhesh K. Mishra, Gary W. Pace, Michael G Vachon
Abstract: The present invention relates to a composition or article containing at least one oxidizing agent and at least one reducing agent, wherein at least one of the at least one reducing agent is a depilatory agent, the equivalent ratio of the at least one oxidizing agent to the at least one reducing agent is less than 1:1, and the article is exothermic when wet with water, and the use thereof to remove hair from the skin.
Type:
Grant
Filed:
September 30, 2002
Date of Patent:
March 7, 2006
Assignee:
Johnson & Johnson Consumer Companies, Inc.
Inventors:
Ying Sun, Diana L. Friscia, Vipul Dave, Elvin R. Lukenbach